利拉鲁肽联合门冬胰岛素治疗难治性2型糖尿病的疗效
|
摘要
目的探讨利拉鲁肽、门冬胰岛素治疗难治性2型糖尿病的疗效。方法选取葫芦岛市中心医院收治的难治性2型糖尿病患者114例为研究对象,随机分为研究组(利拉鲁肽联合门冬胰岛素)与对照组(门冬胰岛素)各57例,比较两组患者的治疗效果。结果治疗后与对照组相比较,研究组空腹血糖、餐后2 h血糖、糖化血红蛋白低,胰岛素使用剂量少,差异均有统计学意义(均P<0.05);研究组有效率(96.49%)较对照组(85.96%)高,研究组不良反应(5.26%)较对照组(19.29%)低,差异均有统计学意义(均P<0.05)。结论对难治性2型糖尿病患者采用门冬胰岛素联合利拉鲁肽治疗临床疗效显著,能有效控制血糖,减少胰岛素使用量,且安全性较高。
Objective To explore the efficacy of liraglutide and insulin aspart in the treatment of refractory type 2 diabetes mellitus. Methods A total of 114 patients with refractory type 2 diabetes mellitus admitted to Huludao Central Hospital were selected as study subjects and randomly divided into study group(liraglutide combined with insulin aspart) and control group(insulin aspart), with 57 cases in each group. The therapeutic effects of the 2 groups were compared. Results Compared with the control group after the treatment, the fasting blood glucose, postprandial 2-hour blood glucose and glycosylated hemoglobin in the study group were lower, and the dosage of insulin was less, with statistically significant difference(P<0.05); the effective rate of the study group(96.49%) was higher than that of the control group(85.96%); the adverse reactions of the study group(5.26%) were lower than that of the control group(19.29%) and the difference was statistically significant(P<0.05).Conclusion The combination of insulin aspart and liraglutide is significantly effective in the treatment of patients with refractory type 2 diabetes mellitus. It can effectively control blood sugar, reduce insulin use and has high safety.
Objective To explore the efficacy of liraglutide and insulin aspart in the treatment of refractory type 2 diabetes mellitus. Methods A total of 114 patients with refractory type 2 diabetes mellitus admitted to Huludao Central Hospital were selected as study subjects and randomly divided into study group(liraglutide combined with insulin aspart) and control group(insulin aspart), with 57 cases in each group. The therapeutic effects of the 2 groups were compared. Results Compared with the control group after the treatment, the fasting blood glucose, postprandial 2-hour blood glucose and glycosylated hemoglobin in the study group were lower, and the dosage of insulin was less, with statistically significant difference(P<0.05); the effective rate of the study group(96.49%) was higher than that of the control group(85.96%); the adverse reactions of the study group(5.26%) were lower than that of the control group(19.29%) and the difference was statistically significant(P<0.05).Conclusion The combination of insulin aspart and liraglutide is significantly effective in the treatment of patients with refractory type 2 diabetes mellitus. It can effectively control blood sugar, reduce insulin use and has high safety.
引文
[1]郑焱,於松达.利拉鲁肽、达格列净联合甘精胰岛素治疗难治性2型糖尿病的疗效及安全性评价[J].现代实用医学,2019,31(2):210-212.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].北京:北京大学医学出版社, 2014:55-56.
[3]炊娟霞,孙晓利,田勇.利拉鲁肽、门冬胰岛素30联用治疗难治性2型糖尿病的临床价值与安全性评价[J].中国医药指南, 2018,16(31):134-135.
[4]贾文芳,李剑.利拉鲁肽联合胰岛素治疗难治性2型糖尿病疗效及安全性评价[J].山西医药杂志, 2018, 47(15):1797-1799.
[5]黄倩,张玲,李佳芮,等.利拉鲁肽联合胰岛素治疗老年难治性2型糖尿病的临床效果[J].中国老年学杂志,2017,37(21):5290-5291.
[6]刘绿,王秋月.利拉鲁肽联合门冬胰岛素30对难治性2型糖尿病的治疗效果观察[J].中国医药指南, 2017, 15(24):26-27.
[7]李荣茂,凌服富.利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的临床效果观察[J].中外医学研究,2017,15(3):112-113.
[8]毛培军,李桂玲,黄倩,等.利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的临床疗效及安全性评价[J].中国临床药理学杂志, 2015,(16):1578-1581.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].北京:北京大学医学出版社, 2014:55-56.
[3]炊娟霞,孙晓利,田勇.利拉鲁肽、门冬胰岛素30联用治疗难治性2型糖尿病的临床价值与安全性评价[J].中国医药指南, 2018,16(31):134-135.
[4]贾文芳,李剑.利拉鲁肽联合胰岛素治疗难治性2型糖尿病疗效及安全性评价[J].山西医药杂志, 2018, 47(15):1797-1799.
[5]黄倩,张玲,李佳芮,等.利拉鲁肽联合胰岛素治疗老年难治性2型糖尿病的临床效果[J].中国老年学杂志,2017,37(21):5290-5291.
[6]刘绿,王秋月.利拉鲁肽联合门冬胰岛素30对难治性2型糖尿病的治疗效果观察[J].中国医药指南, 2017, 15(24):26-27.
[7]李荣茂,凌服富.利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的临床效果观察[J].中外医学研究,2017,15(3):112-113.
[8]毛培军,李桂玲,黄倩,等.利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的临床疗效及安全性评价[J].中国临床药理学杂志, 2015,(16):1578-1581.